Document is current
Any future updates will be listed below
-
Authors
Schaner, Philip E.
Tran, Ly-Binh-An
Zaki, Bassem I.
Swartz, Harold M.
Demidenko, Eugene
Williams, Benjamin B.
Siegel, Alan
Kuppusamy, Periannan
Flood, Ann Barry
Gallez, Bernard
-
Funding
Funding for this research was provided by:
DHHS NIH National Cancer Institute (5P01CA190193-05)
DHHS NIH National Cancer Institute (5P01CA190193-05)
DHHS NIH National Cancer Institute (5P01CA190193-05)
DHHS NIH National Cancer Institute (5P01CA190193-05)
DHHS NIH National Cancer Institute (5P01CA190193-05)
DHHS NIH National Cancer Institute (5P01CA190193-05)
DHHS NIH National Cancer Institute (5P01CA190193-05)
DHHS NIH National Cancer Institute (5P01CA190193-05)
- License Information
-
More Information
Article History
Received: 31 October 2019
Accepted: 25 January 2021
First Online: 24 February 2021
Competing interests
: ABF and HMS report part ownership of Clin-EPR, LLC, during the conduct of the study; Clin-EPR manufactures EPR instruments for investigational use only. PK reports that he has a patent issued for OxyChip, but received no compensation. ED, BG, PS, AS, LBAT, BW and BZ declare no potential conflict of interest.
